Processa Pharmaceuticals Inc has a consensus price target of $3.8, established from looking at the 9 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Benchmark, and Maxim Group on April 25, 2024, March 6, 2024, and November 17, 2023. With an average price target of $4 between HC Wainwright & Co., Benchmark, and Maxim Group, there's an implied 95.12% upside for Processa Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/25/2024 | PCSA | Buy Now | Processa Pharma | $2.05 | 290.24% | HC Wainwright & Co. | Raghuram Selvaraju | → $8 | Initiates | → Buy | Get Alert |
03/06/2024 | PCSA | Buy Now | Processa Pharma | $2.05 | 95.12% | Benchmark | Robert Wasserman | → $4 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
11/17/2023 | PCSA | Buy Now | Processa Pharma | $2.05 | — | Maxim Group | Naz Rahman | — | Downgrade | Buy → Hold | Get Alert |
04/04/2023 | PCSA | Buy Now | Processa Pharma | $2.05 | 95.12% | Benchmark | Aydin Huseynov | $180 → $80 | Maintains | Speculative Buy | Get Alert |
04/03/2023 | PCSA | Buy Now | Processa Pharma | $2.05 | 46.34% | Oppenheimer | Francois Brisebois | $100 → $60 | Maintains | Outperform | Get Alert |
01/12/2023 | PCSA | Buy Now | Processa Pharma | $2.05 | 143.9% | Maxim Group | Naz Rahman | $180 → $100 | Maintains | Buy | Get Alert |
04/19/2022 | PCSA | Buy Now | Processa Pharma | $2.05 | 339.02% | Maxim Group | Naz Rahman | → $180 | Initiates | → Buy | Get Alert |
08/03/2021 | PCSA | Buy Now | Processa Pharma | $2.05 | 875.61% | Oppenheimer | Francois Brisebois | → $400 | Initiates | → Outperform | Get Alert |
08/02/2021 | PCSA | Buy Now | Processa Pharma | $2.05 | 875.61% | Oppenheimer | Francois Brisebois | → $400 | Initiates | → Outperform | Get Alert |
The latest price target for Processa Pharma (NASDAQ: PCSA) was reported by HC Wainwright & Co. on April 25, 2024. The analyst firm set a price target for $8.00 expecting PCSA to rise to within 12 months (a possible 290.24% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Processa Pharma (NASDAQ: PCSA) was provided by HC Wainwright & Co., and Processa Pharma initiated their buy rating.
There is no last upgrade for Processa Pharma.
The last downgrade for Processa Pharmaceuticals Inc happened on November 17, 2023 when Maxim Group changed their price target from N/A to N/A for Processa Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharma was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
While ratings are subjective and will change, the latest Processa Pharma (PCSA) rating was a initiated with a price target of $0.00 to $8.00. The current price Processa Pharma (PCSA) is trading at is $2.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.